Skip to content

Canadian Real-World Evidence: Observational 24-Week Outcomes for Health Care Practitioner Authorized Cannabis

Real-world evidence offers valuable insight into how medical cannabis performs outside randomized controlled trials, capturing outcomes across diverse patient populations and product types to help inform real-world clinical decision making.

Read the Study

ONTARIO SECURITIES COMMISSION APPROVES AVICANNA’S APPLICATION FOR MANAGEMENT CEASE TRADE ORDER

Driving Biopharmaceutical Advancement
of Evidence-Based, Cannabinoid Products

Who We Are

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products. with a focus on the medical and pharmaceutical market segments at an international level, Avicanna has established an industry leading scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

•AN IMPORTANT STATEMENT FROM AVICANNA •

MEDICAL CANNABIS
IN VETERAN'S CARE:

CLINICAL INSIGHTS AND IMPLICATIONS OF
PROPOSED REIMBURSEMENT CHANGES

Integrated Cannabinoid-Based Biopharmaceutical Platform

Commercial & Medical Platform

4 integrated commercial-stage business units

50+ proprietary commercialized cannabinoid products

Commercial presence across 20+ international markets

$25.5M revenue, near EBITDA breakeven during 2025

Scientific & Clinical Platform

Proprietary intellectual property and formulation technologies

Clinical and real-world evidence programs

Partnerships with leading academic and clinical institutions

Indication-specific pharmaceutical pipeline

Core Business Units

Medical Cannabis Products (RHO Phyto™)

Medical Cannabis Care Platform (MyMedi.ca)

Pharmaceutical Pipeline (Clinical Development)

Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Four Commercial Stage Business Units

Avicanna’s Scientific Platform Has Resulted In 50+ Proprietary Formulations and Commercial Products

A vertically integrated platform spanning API, R&D, clinical development, and patient care.

Medical Cannabis Care Platform

Medical Cannabis Products

Pharmaceutical Pipeline
Active Pharmaceutical Ingredients

Established Scientific Platform & Institutional Validation

Supporting the Development of Evidence-Based Cannabinoid Therapeutics

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products 

50+ Proprietary 
Commercial Products

10+ Scientists

Extensive Pharmaceutical
Pipeline

IP Portfolio including
USPTO granted patents

11 Government Grants and 20+ R&D Collaborations

100% Ownership of
All IP and Trade Secrets

Academic and Clinical Collaborations Since 2017

World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017
Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.
avicanna9
sunnybrooklogo
ccic
langara-logo
canadian-pain-society-1

Clinical Development

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products

08.08.2021

Products & Pipeline

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products

[show-logos orderby=’none’ category=’0′ activeurl=’same’ style=’normal’ interface=’hcarousel’ tooltip=’false’ description=’false’ limit=’0′ padding=’10’ filter=’false’ carousel=’true,4000,true,false,500,150,true,false,true,1,4,1′]